Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort

被引：0

作者：

Canavesi, Giada ^{[1
]}

Mena, Maurizio ^{[1
]}

Zaninetta, Elena ^{[2
,3
]}

Gazzola, Lidia ^{[2
,3
]}

Bini, Teresa ^{[2
,3
]}

Orofino, Giancarlo ^{[4
,5
]}

De Vito, Andrea ^{[6
,7
]}

Madeddu, Giordano ^{[6
,7
]}

Grillo, Chiara ^{[8
,9
]}

Bartalucci, Claudia ^{[10
,11
]}

Centorrino, Federica ^{[10
,11
]}

Squillace, Nicola ^{[12
,13
]}

Bonfanti, Paolo ^{[12
,13
]}

Tiecco, Giorgio ^{[14
,15
]}

Foca, Emanuele ^{[14
,15
]}

Menozzi, Marianna ^{[16
,17
]}

Guaraldi, Giovanni ^{[16
,17
]}

Bana, Nicolas Brian ^{[18
]}

Cavazza, Giovanni ^{[18
]}

Rossotti, Roberto ^{[18
]}

Lo Caputo, Sergio ^{[8
,9
]}

Di Biagio, Antonio ^{[10
,11
]}

Rusconi, Stefano ^{[1
]}

机构：

[1] Osped Nuovo Legnano, Infect Dis Unit, ASST Ovest Milanese, Legnano, Italy

[2] San Paolo Hosp, Infect Dis Unit, ASST Santi Paolo & Carlo, Milan, Italy

[3] Dipartimento Sci Salute, Milan, Italy

[4] Amedeo Savoia Hosp, Infect Dis Unit, Turin, Italy

[5] Univ Turin, Turin, Italy

[6] Azienda Osped Univ Sassari, Infect Dis Unit, Sassari, Italy

[7] Univ Sassari, Sassari, Italy

[8] Azienda Osped Univ Osped Riuniti Foggia, Infect Dis Unit, Foggia, Italy

[9] Univ Foggia, Foggia, Italy

[10] Osped Policlin San Martino, Infect Dis Unit, Genoa, Italy

[11] Univ Genoa, Genoa, Italy

[12] IRCCS San Gerardo Tintori, Infect Dis Unit, Monza, Italy

[13] Univ Milano Bicocca, Monza, Italy

[14] Spedali Civili Brescia, Infect Dis Unit, Brescia, Italy

[15] Univ Brescia, Brescia, Italy

[16] Azienda Osped Univ Modena, Infect Dis Unit, Modena, Italy

[17] Univ Modena & Reggio Emilia, Modena, Italy

[18] ASST Grande Osped Metropolitano Niguarda, Infect Dis Unit, Milan, Italy

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P074

引用

页码：86 / 88

页数：3

共 50 条

[41] Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk
Masia, Mar
Fernandez-Gonzalez, Marta
Ledesma, Christian
Losada-Echeberria, Maria
Gonzalo-Jimenez, Nieves
Mascarell, Paula
Garcia-Abellan, Javier
Lopez, Leandro
Bello-Perez, Melissa
Padilla, Sergio
Gutierrez, Felix
JOURNAL OF INFECTIOUS DISEASES, 2025,
[42] HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings
Washaya, Tendai
Manasa, Justen
Kouamou, Vinie
AIDS, 2023, 37 (10) : 1629 - 1631
[43] What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
Bettonte, Sara
Berton, Mattia
Marzolini, Catia
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (05) : 243 - 247
[44] Switching to long-acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine: a substudy from the RELATIVITY cohort
Galindo Puerto, Maria Jose
Buzon Martin, Luis
Troya, Jesus
Martin-Carbonero, Luz
Bermejo Plaza, Laura
Torralba, Miguel
Montero Hernandez, Carmen
De Zarraga Fernandez, Miguel Alberto
Pedrero Tome, Roberto
Cabello Clotet, Noemi
Arenas Garcia, Victor
Garcia Abellan, Javier
Cabello Ubeda, Alfonso
Losa Garcia, Juan Emilio
Crusells-Canales, Maria Jose
Llenas-Garcia, Jara
De la Calle Riaguas, Beatriz
Morano, Luis
Aguilera Garcia, Maria
Martin Rico, Patricia
Bernal, Enrique
De la Fuente Moral, Sara
Calderon Hernaiz, Ruth
Antonia Sepulveda, Maria
Menchi, Marouane
Clavero Olmos, Marta
Gutierrez Cuadra, Manuel
Estebanez, Miriam
Alonso Moreno, Barbara
Cecilio, Alvaro
Egido Murciano, Miguel
Cuevas Tascon, Guillermo
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 113 - 115
[45] Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy
Gutierrez, Felix
Fernandez-Gonzalez, Marta
Ledesma, Christian
Losada-Echeberria, Maria
Barrajon-Catalan, Enrique
Masia, Mar
CLINICAL INFECTIOUS DISEASES, 2025,
[46] Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection
Zeuli, John D.
Rivera, Christina G.
Smith, Bradley L.
Otto, Ashley
Temesgen, Zelalem
DRUGS OF TODAY, 2022, 58 (12) : 555 - 576
[47] Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China
Li, Mengqing
Guan, Hongjing
Zhong, Mingli
Di, Xiaoyun
Yu, Nawei
Chen, Chen
Cai, Rentian
Wei, Hongxia
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2025, 41 (02) : 107 - 112
[48] Direct switch from an efavirenz-based regimen to intramuscular long-acting cabotegravir plus rilpivirine: A case report
Senkoro, Elizabeth
Bracchi, Margherita
Heskin, Joseph
Walters, Yasmin
Varadarajan, Maithili
Antoniadi, Christina
Al-Shakarchi, Yaser
Girometti, Nicolo
Boffito, Marta
INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (04) : 311 - 313
[49] Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
Ahluwalia, Amrit Kaur
Inzaule, Seth
Baggaley, Rachel Clare
Vitoria, Marco
Schaefer, Robin
Schmidt, Heather-Marie Ann
Rodolph, Michelle
Giron, Amalia
Jordan, Michael R.
AIDS, 2022, 36 (13) : 1897 - 1898
[50] Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modelling Study
Bettonte, Sara
Berton, Mattia
Stader, Felix
Battegay, Manuel
Marzolini, Catia
CLINICAL INFECTIOUS DISEASES, 2023, 76 (07) : 1225 - 1236

← 1 2 3 4 5 →